Kymera IPO Presentation Deck

Rheumatic Diseases UNMET MEDICAL NEED Many unmet medical needs across various cancers and rheumatological, dermatological disorders KYMERA Rheumatologic THE LANCET -10: CANTOS Data Atherosclerosis, OURNAL MEDICINE Lung Cancer Allergy Clinical L-18: Macrophage Immunology Activation Syndrome IL-IR Drug Development Principles IL-1R/TLR Pathway FAMA Mycen IL-1 IL-18 IL-33 IL-36 VALIDATED BIOLOGY Clinically validated areas: oncology. immunology, fibrosis MYDS8 Mutations: Home One Generalized Pustular Psoriasis Atopic Dermatitis SCIENTIFIC REPORTS NEW ENGLAND Allergy Clinical Immunology AAD UN-DRUGGED NODE Key un-drugged or inadequately drugged nodes that TPD can unlock IL-6R: IL-6: Multicentric Rheumatoid Castleman's Arthritis Disease ACTEMRA sylvant JAK1/2: Myelofibrosis Jakafi Ⓒ JAK3: Alopecia Areata Pfizer IL-AR 20 JAK SAK JAK-STAT Pathway PRECISION MEDICINE APPROACH JAK Targeted to a genetically defined patient population JAK STATE STATS STATE STATS STAT3: Activating Mutations ATE genetics TYK2 JOURNAL MEDICINE TYKZ: Autoimmune Disease NEW ENGLAND JOURNAL MEDICINE STATS ASO AZD9150 in Oncology Journal for ImmunoTherapy of Cancer STAT3: Activation (pSTAT3) Blood Cancer Journal

View entire presentation